Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Cash & Equivalents (2016 - 2025)

Altimmune (ALT) has disclosed Cash & Equivalents for 16 consecutive years, with $43.8 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 18.49% to $43.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $43.8 million through Dec 2025, up 18.49% year-over-year, with the annual reading at $43.8 million for FY2025, 18.49% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $43.8 million at Altimmune, down from $61.2 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $190.3 million in Q4 2021, with the low at $31.5 million in Q3 2024.
  • Average Cash & Equivalents over 5 years is $110.7 million, with a median of $107.9 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents surged 1226.04% in 2021, then tumbled 72.65% in 2024.
  • Over 5 years, Cash & Equivalents stood at $190.3 million in 2021, then crashed by 41.61% to $111.1 million in 2022, then rose by 21.62% to $135.2 million in 2023, then crashed by 72.65% to $37.0 million in 2024, then increased by 18.49% to $43.8 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $43.8 million, $61.2 million, and $183.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.